ACUMEN PHARMACEUTICALS INC

ABOSNASDAQ

🏆 #2816 by market capUS Equity

$2.47▲ $0.04 (+1.65%)

Live

1h—

24h▲ 1.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$178M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

121.9x

Expensive

Otter Score

Fair

No chart data available for ABOS.

Trading Snapshot

Day Range: $2.45 – $2.49
52-Week Range: $1.19 – $3.60
Volume: $5.03B
Avg Volume: $5.64B
Shares Outstanding: 72.2M
Next Earnings: Sep 24, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $355,255
P/E Ratio: —
P/S Ratio: 121.9x
EPS (TTM): $-1.86
Dividend Yield: —

Why Investors Own ABOS

✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
✓Healthy economics — 56% gross margin and 4% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1M▲ +11.1% YoY

Gross Margin (TTM)

55.6%▲ +3.9% YoY

Operating Income (TTM)

$365,926▲ +11.1% YoY

Free Cash Flow (TTM)

$61,476▲ +11.1% YoY

About ACUMEN PHARMACEUTICALS INC

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

🦦